Autobio Diagnostics (603658) Q4 2025 earnings summary

Executive summary

• Revenue for 2025 was RMB 4.23 billion, down 5.47% year-over-year; net profit attributable to shareholders was RMB 1.07 billion, down 10.59% year-over-year.

• R&D investment reached RMB 767.6 million, accounting for 18.16% of revenue, with 2,005 R&D staff (35.18% of total employees).

• The company maintained a leading position in IVD innovation, with 197 new reagent product registrations and 7 new instrument registrations.

• Cash dividend payout for the year was RMB 748.6 million, with total cash return (including buybacks) at 70.94% of net profit.

Financial highlights

• Gross margin for IVD business was 66.20%, up 0.17 percentage points year-over-year.

• Basic and diluted EPS were RMB 1.87, down 9.66% year-over-year.

• Operating cash flow was RMB 1.34 billion, up 2.47% year-over-year.

• Net assets attributable to shareholders at year-end were RMB 8.93 billion, up 3.59% from prior year.

• Quarterly revenue and profit showed a sequential decline in Q4.

Outlook and guidance

• The company expects continued pricing pressure from centralized procurement and intensified competition in 2026.

• Strategic focus remains on R&D efficiency, product line expansion (sequencing, mass spectrometry, POCT), and sales network optimization.

• Industry trends favor domestic substitution, high-end technology adoption, and market consolidation.